anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients will undergo anesthesia induction as routine after premedication. The level of sevoflurane, an inhalation gas, will be adjusted so that BIS values are between 40-60. Patients will receive controlled ventilation with 50% oxygen/air, and mechanical ventilation parameters will be adjusted so that the end tidal carbon dioxide level (EtCO2) is 35-45 mmHg.
Patients in Group B (intervention CEZ) were given AMP of 1g CEZ intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose CEZ was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
Basic aluminium chlorides of the formula Al2OHnCl6-n (where n is a number between 4 and 5) are prepd. by treating aq. solns. contg. Aluminium chloride with solns. of amines (in effect a liquid ion-exchanger, having advantages of insensitivity to impurities and ease of regeneration of molecular weight 250-500 (pref. primary, secondary or tertiary monoamines) in a water-immiscible organic solvent (pref. petroleum, kerosene or xylene), separating the aq. phase and recovering the basic aluminium chloride. The aq. phase must not contain >25 g Al per litre, and the organic phase must not contain > 0.35 mol amine per litre. Basic aluminium chlorides are used in the cosmetic and pharmaceutical sectors as components of antiperspirants and haemostatic agents. They are also used for hydrophobizing textiles, as tanning agents, as flocculating and phosphate-precipitating agents, and in the production of fire resistant materials.
The present invention discloses a kind of liver cancer cell apoptosis inducing factor and its encoding gene and use. The liver cancer cell apoptosis inducing factor is protein with the amino acid residue sequence of SEQ ID No. 2 in the sequence list or SEQ ID No. 2 derived protein with the same activity as that of the amino acid residue sequence of SEQ ID No. 2. The coding gene is one of the following nucleotides sequences: 1) the DNA sequence of SEQ ID No. 1 in the sequence list; 2) polynucleotides encoding the protein sequence of SEQ ID No. 2 in the sequence list; 3) DNA sequence with over 90 % homology with the DNA sequence of SEQ ID No. 1 in the sequence list and encoding the same functional protein. The liver cancer cell apoptosis inducing factor of the present invention SAPL and its coding gene may be used in preparing liver cancer preventing and treating medicine.
PURPOSE:To obtain a liver function improver useful for long-term administration, preventing or improving deterioration of disease state by administration during hepatic diseases, having no side effects, comprising a fermented metabolite of a bacterium belonging to the genus Lactobacillus as an active ingredient. CONSTITUTION:An liver function improver containing a fermented metabolite of Lactobacillus bifidus as an active ingredient. Lactobacillus longus may be cited as the bacterium belonging to the genus Lactobacillus. A fermented metabolite of a bacterium belonging to the genus Lactobacillus obtained by inoculating and cultivating the bacterium in a medium containing de-fatted powdered milk is used. The active ingredient is used alone or combined and directly administered. For example, the active ingredient is administered as a preparation composition such as solution or capsule. A dose is 1-10g per adult daily in oral administration and 100-2,000mg in intramuscular or blood administration.
Lack of access to blood transfusions is a key barrier to timely hospice use for patients with blood cancers. Refractory anemia and thrombocytopenia are common for patients with blood cancers and result in debilitating fatigue, shortness of breath, and bleeding. Transfusions palliate these symptoms and improve quality of life (QOL); yet, most hospices do not provide access to transfusions. Patients are thus faced with the agonizing choice of preserving access to vital palliative transfusions versus accessing quality home-based hospice care. Patients with blood cancers and their caregivers report that transfusions are vital for their quality of life, and that access to transfusions is a key factor in deciding whether to opt for hospice care.

The study team has thus developed a new model of care (HEME-Hospice) that provides access to palliative home transfusions to patients with hematologic malignancies who are enrolled in hospice. The purpose of this study is to determine whether access to HEME-hospice versus usual care improves hospice enrollment rates, quality of life (QOL), mood, and end-of-life healthcare utilization for patients with hematologic malignancies as well as QOL and mood of their caregivers. This study is a cluster randomized trial in which hematologic oncologists will be randomly assigned to access to HEME-Hospice versus usual care. Participants in this study will have access to HEME-hospice or usual care based upon the strategy to which their hematologic oncologist has been assigned.
PURPOSE: A Korean mulberry-derived polysaccharide which enhances immunity, and a pharmacological composition containing the same are provided to enhance immunity without cytotoxicity, and to be used as a material for pharmaceutical products, functional foods, and functional cosmetic products. CONSTITUTION: A pharmaceutical composition for enhancing immunity contains polysaccharides including: a main chain including basic skeleton of methyl group-conjugated alpha-1,4-galacturonic acid and alpha-1,2-rhamnose; and a side chain including 5-linked alpha-arabinose, 4-linked beta-galactan, and arabinogalactan. The polysaccharide is derived from Morus spp. using ethanol. The pharmaceutical composition contains rhamnose, arabinose, galactose, and galacturonic acid as monosaccharides forming the polysaccharides. The polysaccharide enhances expression of IL-6 and TNF-alpha.
TTCM will provide 8 weeks of nicotine replacement therapy at hospital discharge and proactive contacts over 3 months delivered by automated IVR call. At each contact the patient is offered a return call from the hospital-based tobacco coach for counseling, medication advice, and coordination of care with the patient's outpatient health care team.
Psychosis typically emerges in late adolescence or early adulthood, during a vital stage in social and cognitive development, which can have a profoundly adverse impact on an individual's long-term functioning. Numerous studies find a substantial delay between the onset of psychosis and the initiation of specialty treatment for first episode psychosis (FEP), with the duration of untreated psychosis (DUP) typically over one year in the U.S. Better detection strategies are needed to improve identification of individuals with FEP and to rapidly engage them in Coordinated Specialty Care (CSC) aimed at restoring functioning. The onset of psychosis is preceded by a prodromal phase characterized by attenuated psychotic symptoms and decline in functioning. This phase (at-risk mental state: ARMS) is a potential target for strategies aimed at improving outcome by reducing DUP through regular symptom monitoring. This study will investigate whether a U.S. adaptation of a successful detection approach from the Netherlands can reduce DUP in the U.S. setting. The Dutch study found that screening of a consecutive help-seeking population entering mental health services captures significantly more FEP and ARMS cases than clinician referrals from mental health centers. Therefore screening may be an effective strategy for identifying individuals with psychotic symptoms earlier on in the course of their illness. This study will implement and evaluate a systematic screening for psychotic symptoms in community mental health clinics in order to facilitate rapid identification and engagement in treatment of individuals with FEP. Individuals ages 12 to 30 entering child/adolescent and adult community mental health clinics (CMHCs) within Mount Sinai Health System will be screened with the Prodromal Questionnaire - Brief Version (PQ-B). Those who screen positive will be assessed by the Structured Interview for Prodromal Syndromes (SIPS) and referred to stage-specific specialty care. Individuals with FEP will be referred to CSC programs: OnTrackNY and PEER. Individuals with ARMS will be monitored and referred to ICanFeelBetter program for ARMS. DUP will be measured for all individuals who meet SIPS psychosis criteria. The study team hypothesizes that screening for psychotic symptoms in CMHCs will be feasible and acceptable, and that the average DUP of FEP individuals identified with screening will be less than 3 months, the maximum time between onset of psychotic symptoms and engagement in CSC recommended by the World Health Organization. In order to optimize screening and treatment engagement strategies for reducing DUP, the clinical team will identify facilitators and barriers to FEP care through in-depth qualitative interviews with patients and caregivers, and by mapping pathways to FEP care. The study team will also conduct in-depth qualitative interviews with clinicians to explore their experience with the screening and referral process.
The use of fibrin glue for inguinal hernia mesh fixation has been suggested to be effective in preventing hematomas and reducing postoperative pain compared to tacks and sutures.. The effect of fibrin glue can vary significantly based on the device used. This study assessed the efficacy of fibrin glue based on the type of devices used in an ex vivo system. The rabbit's abdominal wall was trimmed to a size of 3.0 × 6.0 cm and was secured at the edges with metal fixtures. To measure the maximum tensile strength at the point of adhesion failure, the hernia mesh was fixed to the rabbit's abdominal wall using fibrin glue in a 2 cm square area, left for 3 min, and then pulled at a speed of 50 cm/min. The test was conducted 10 times for each group. The median (minimum-maximum) tensile strength values using the spraying, two-liquid mixing, and sequential layering methods were 3.58 (1.99-4.95), 0.51 (0.27-1.89), and 1.32 (0.63-1.66) N, respectively. The spraying method had predominantly higher tensile strength values than the two-liquid mixing and sequential layering methods (P < 0.01). In conclusion, in hernia mesh fixation, the spraying method can be adopted to achieve appropriate adhesive effects.
Selegiline hydrochloride is a levorotatory acetylenic derivative of phenethylamine. It is commonly referred to in the clinical and pharmacological literature as l-deprenyl.

The chemical name is: (R)-(-)- N,2-dimethyl- N-2-propynylphenethylamine hydrochloride. It is a white to near white crystalline powder, freely soluble in water, chloroform, and methanol, and has a molecular weight of 223.75. The molecular formula is C 13H 17•HCl. The structural formula is as follows: 

Each tablet, for oral administration, contains 5 mg selegiline hydrochloride. Inactive ingredients are citric acid, anhydrous lactose, magnesium stearate, and microcrystalline cellulose.
Obesity was mainly regarded as a disease of developed countries, but currently there is a growing rise in the population of patients with obesity in developing countries of Africa. A body mass index of 30 kg/m2 or higher is regarded as obesity, and this may be associated with comorbidities such as metabolic and cardiovascular diseases, orthopaedic and psychiatric conditions, and cancer. There is conclusive scientific evidence that shows that obesity is caused by complex psychosocial, genetic and environmental factors. Diet and exercise are not effective as sole management of severe obesity. Bariatric surgery is the most cost-effective definitive treatment for all classes of obesity, and the associated weight reduction causes improvement or complete resolution of obesity-associated comorbidity, improves the quality of life and reduces all-cause mortality. It is estimated that about 15% of adults in Nigeria are obese, and in the year 2023, it was reported that only 214 bariatric procedures were done locally, with 134 (62.6%) being gastric balloon insertions, 75 (35.1%) primary weight loss surgeries and 5 revisional surgeries (2.3%). In this article, we discussed the existing weight loss options in Nigeria, the current state of bariatric surgery and the need to improve the practice of bariatric surgery for obese Nigerians and complications of obesity.
There is provided a method comprising orally administering a composition before and/or during exercise. The composition contains a casein hydrolysate containing a free amino acid and a peptide, or a mixture of the free amino acid and the peptide. The casein hydrolysate is produced by hydrolyzing an animal milk casein, and has an average chain length of 2.1 or less in terms of the number of amino acid residues. There is further provided an oral composition for use in the method. The oral composition contains, as an active ingredient, a casein hydrolysate containing a free amino acid and a peptide, or a mixture of the free amino acid and the peptide. The casein hydrolysate is produced by hydrolyzing an animal milk casein, and has an average chain length of 2.1 or less in terms of the number of amino acid residues. There is still further provided the use of the oral composition for inhibiting increase in heart rate during exercise.
The invention relates to a hydrocortisone-RGD polypeptide conjugate shown in a general formula i, and a preparation method and application thereof. In the general formula i, RGDX is tetrapeptide Arg-Gly-Asp-X, and X is any one of three amino acids of Val, Phe and Ser. Experiments prove that the compound provided by the invention has excellent immunological suppression effect and anti-inflammatory effect and the side effect of osteoporosis is reduced. The compound can be clinically used as an immunological suppressant and anti-inflammatory agent having low side effect of osteoporosis. Meanwhile, the hydrocortisone-RGD polypeptide conjugate can form nano spheres having a stable particle diameter of 200-700 nm through self assembly in a water solution. Thus, the hydrocortisone-RGD polypeptide conjugate can be prepared into an immunological suppression pharmacosome, microemulsion or liposome targeted medicament.
The invention provides a method of regulating water and mucin secretions and fluid transport in the gastrointestinal tract. The invention also provides a method for treating a gastrointestinal disease in which the mucosal barrier of the gastrointestinal system is impaired. The invention additionally provides a method for correcting disorders of fluid secretion or absorption in the gastrointestinal system. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor agonist, in an amount effective to regulate water and mucin secretions or to correct abnormal fluid transport in the gastrointestinal tract. The pharmaceutical composition used in this invention comprises a P2Y purinergic receptor agonist such as uridine 5′-diphosphate (UDP), uridine 5′-triphosphate (UTP), cytidine 5′-diphosphate (CDP), cytidine 5′-triphosphate (CTP), adenosine 5′-diphosphate (ADP), adenosine 5′-triphosphate (ATP), and their analogs; and dinucleotide polyphosphate compounds of general Formula (IV). Said compound is prepared in an oral form, an injectable form, or a suppository form, and administered to a patient.
GPs of the intervention group will dedicate an average 5 minutes during the consult to perform OS-UDT. Patients will be asked to collect a urine sample at the GP's medical office. GP will read and communicate the results immediately to the patients. GPs will keep free of their management according to OS-UDT results.
FIELD: medicine, oncology, virology, pharmacology. SUBSTANCE: invention relates to pharmaceutical composition comprising derivative of benzimidazole of the formula (I)   where R, R 2 , X, Y and n have values given in the invention claim. Composition inhibits growth of tumors and malignant neoplasms in mammals. Composition is used in combination with chemotherapeutic agent where potentiating agents can be included also. Invention relates also to composition of standard medicinal form and method of treatment of malignant neoplasms, tumors and viral infections. Composition exhibits efficiency in leucosis treatment being without effect or with mild effect on normal blood cells. EFFECT: enhanced effectiveness of composition and treatment, valuable medicinal properties. 18 cl, 3 tbl, 2 ex
Considerable concern now exists over possible effects on human physical and psychological development of endocrine disrupting environmental contaminants such as polychlorinated biphenyls (PCBs). Native American communities are particularly at risk owing to subsistence systems and a cultural ethos involving greater contact with the physical environment. The proposed study follows-up 220 Mohawk adolescents aged 17-21 years, who participated in a previous study when they were 10-16 years old. All adolescents are members of the Mohawk Nation at Akwesasne which is located on the St. Lawrence River and is adjacent to hazardous waste sites where PCBs have contaminated the local ecology. The investigation examines the interrelationship between Mohawk cultural identity, traditional Mohawk customs, behaviors related to toxicant exposure and current toxicant burden. Serum level of PCBs will be assessed by congener specific analysis. The study will determine the relationship of congeners and their hydroxylated metabolites to thyroid function (levels of triiodothyronine, free triiodothyronine, thyroxine, free thyroxine, thyrotropin and anti-thyroid antibodies), and 2) psychosocial outcomes including school behavior and performance, hyperactivity, and adaptation to the community. Data gathered for the past study will be employed to assess variation in metabolism of PCBs, as well as how earlier measures of cognition and hyperactivity relate to 17 year old psychosocial outcomes. Variation in susceptibility to PCB effects will be determined by examining the effects of concurrent toxicant exposure (hexachlorobenzene, Mirex, dichlorodiphenyldichloroethene, lead), diet, and indicators of PCB metabolism, on the focal measures of adult functioning. The proposed study will clarify the causal pathways between culturally identifying behavior, PCB exposure and body burden, thyroid functioning, cognitive functioning, social behavior and school functioning while identifying activities that are important to maintain cultural identify and unrelated to exposure.
Many patients who take oral medication to treat schizophrenia or schizoaffective disorder have trouble taking their medication every day. They may not want to take it, or they may just forget. Risperidone injections, given once every 2 weeks, are expected to be just as effective as risperidone tablets taken once a day. The option of getting an injection every 2 weeks rather than taking a tablet every day may help patients keep to their medication administration schedule and could help to reduce the symptoms of their disease. The study will assess the usefulness of the Risperdal® Consta® Treatment Guidebook in a Community Mental Health Center setting, over a period of three months. This Guidebook was designed to help doctors switch adult patients from oral risperidone tablets to long-acting risperidone given once every 2 weeks by injection. During the study, patients will continue to take oral risperidone for 2 weeks following initiation of risperidone injections, which will be given every 2 weeks during a 12-week period. Physical examinations and laboratory tests will be performed to test the safety of the risperidone injections. Both the patient and the doctor will be asked questions about the usefulness of the guidebook and the effectiveness of the injections. The objective of this study is to demonstrate the effectiveness of the Risperdal® Consta™ Treatment Guidebook in switching patients with schizophrenia and schizoaffective disorder from daily oral risperidone to long-acting risperidone injections. In addition, safety evaluations are assessed throughout the study. Risperidone oral tablets, 2 to 6 milligrams per day for the first 2 weeks after initiation of long-acting risperidone injections; long-acting risperidone injections are given in doses of 25, 37.5, or 50 milligrams per 2 milliliter injection once every 2 weeks for 12 weeks.
Despite recent advances in neuroimaging, approximately 2/3 of intractable epilepsy patients that undergo surgical evaluation continue to require intracranial EEG (IEEG), arguably the most invasive diagnostic test in medicine. Clinicians currently lack methods to quantitatively map noninvasive imaging measures of structure and function to IEEG. Specifically, there is a critical need to validate whole-brain noninvasive neuroimaging network- based biomarkers to guide precise placement of electrodes and translate noninvasive network neuroimaging to change the paradigms of clinical care. The long-term goal of this study is to predict IEEG functional dynamics and surgical outcomes using noninvasive MRI-based measures of structure and function. The investigators' overall objective, which is the next step toward attaining the study's long-term goal, is to develop open-source noninvasive imaging tools that map epileptic networks by integrating MRI and IEEG data. The central hypothesis is that noninvasive measures of structure and function relate to and can predict the intricate functional dynamics captured on IEEG. The central hypothesis will be tested in patients undergoing IEEG targeting the temporal lobe network by pursuing three specific aims: 1) To map the patient specific structural connectome to IEEG seizure onset and propagation, 2) To correlate seizure onset and propagation on IEEG with network measures derived from resting state functional MRI (rsfMRI), and 3) To integrate the structural (Aim 1) and functional (Aim 2) connectome with standard qualitative clinical data to predict IEEG network dynamics and surgical outcomes. Under the first aim patients will undergo diffusion tensor imaging (DTI) prior to stereotactic IEEG, an IEEG method that inherently samples long range networks. The functional IEEG network will be mapped to DTI thus defining how seizures are constrained by the underlying structural connectome as they propagate. Under the second aim patients with temporal lobe epilepsy will undergo rsfMRI on 7T MRI prior to stereotactic IEEG. Functional network measures from rsfMRI and IEEG will be coregistered and rsfMRI will be used to predict functional EEG ictal and interictal networks. In the third aim two models predicting IEEG network dynamics and epilepsy surgical outcomes will be created building off of methods developed in Aims 1 and 2. This research is innovative because it represents a substantive departure from the status quo by directly connecting noninvasive multimodal imaging with measures of functional network dynamics in IEEG. This research is also significant because it is expected that successful completion of these aims will yield personalized strategies for IEEG targeting based on noninvasive neuroimaging.
Apparatus and method for receiving and transmitting streaming live imagery data and audio signals in real time is provided. Imagery data and audio signals are acquired through a telestreamer input device and streamed to one or more remote recipients, allowing remote operators to electronically collaborate by telestrating, annotating, and sketching image overlays. Streaming video images displayed on a monitor are superimposed onto a virtual mesh projected via computer graphics. Vertices of the virtual mesh move according to a computational physics engine. Virtual tools are also superimposed onto a virtual mesh projected via computer graphics. The virtual tools interact with the virtual mesh to deliver real time, realistic modifications of the streaming image data. Recursive positioning of mesh layers and creation of a multi-layered virtual mesh enhance the realistic nature of the modified streaming image data.